An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy

Abstract

Nanoparticles (NPs) are promising drug delivery systems (DDS) for identifying and treating cancer. Active targeting NPs can be generated by conjugation with ligands that bind overexpressed or mutant cell surface receptors on target cells that are poorly or not even expressed on normal cells. Receptor-mediated endocytosis of the NPs occurs and the drug is released inside the cell or in the surrounding tissue due to the bystander effect. Antibodies are the most frequently used ligands to actively target tumor cells. In this context, antibody-based therapies have been extensively used in HER2+ breast cancer. However, some patients inherently display resistance and in advanced stages, almost all eventually progress. Functionalized NPs through conjugation with antibodies appear to be a promising strategy to optimize targeted therapies due to properties related to biocompatibility, suitable delivery control and efficiency of functionalization. This review is focused on the different strategies to conjugate antibodies into polymeric NPs. Recent antibody conjugation approaches applied to the improvement of breast cancer therapy are highlighted in this review.

Polyester Polymeric Nanoparticles as Platforms in the Development of Novel Nanomedicines for Cancer Treatment

“…Another option is the surface modification by conjugation techniques. Many polymeric NPs have successfully added moieties, such as antibodies, glucose, or proteins, to direct their delivery [ 77 , 78 ].…”

In Vivo PET Imaging of Monocytes Labeled with [89Zr]Zr-PLGA-NH2 Nanoparticles in Tumor and Staphylococcus aureus Infection Models

“…One strategy to enhance overall cellular uptake would be to modify the coating of NPs with, for example, cell-penetrating peptides or Lipofectamine [42][43][44]. Alternatively, to improve labeling of specific subsets of immune cells, NPs can be decorated with antibodies or peptides with the desired specificity [45,46].…”

Rational design of aqueous conjugated polymer nanoparticles as potential theranostic agents of breast cancer

“…44,45 Generally, most breast cancer diagnoses are related to luminal tumors, 20% relates to those that overexpress HER2, while only 15% refers to TNBC subtype. 44 Even though the percentage of TNBC tumors among all breast cancer cases is relatively low, they represent the most aggressive phenotype 46 with the highest rate of metastasis to other healthy organs, high proliferative index, high recurrence rate (o5 years), 47 and a worse prognosis. 48 Nowadays, the most common treatments for TNBC patients include surgery, radiotherapy and chemotherapy.…”